Zimmer Biomet Raises 2026 Outlook After Strong Second Quarter
Zimmer Biomet Holdings reported second quarter net sales of $2.177 billion, a 4.8% increase that prompted the Warsaw-based medical technology firm to lift its full-year financial guidance. The company cited consistent innovation cycles and successful commercial transformations as primary drivers for the improved annual revenue and earnings projections.
The company’s diluted earnings per share hit $1.03 for the period ending June 30, marking a 33.8% jump compared to the same quarter last year. While adjusted diluted earnings per share remained steady at $2.07, the firm generated $447.9 million in operating cash flow, bolstered by healthy underlying market demand across its core segments.
Chairman and CEO Ivan Tornos credited the momentum to the company's ongoing commercial shifts and a robust innovation pipeline. Notable recent milestones include FDA 510(k) clearance for the next-generation ROSA Shoulder System and a $1 billion increase in anticipated share repurchases for 2026. Looking ahead, Zimmer Biomet has tightened its full-year revenue growth forecast to a range of 3.9% to 4.9%, up from previous estimates of 2.5% to 4.5%.
Comments (0)
No comments yet. Be the first!